|
|
One Penn Center, 1617 JFK Blvd., 6th Floor
Philadelphia, PA 19103 USA
phone:(215) 988-0080
fax:(215) 988-1739
|
|
| Symbol |
HEB |
| Exchange |
AMEX |
| Founded |
0 |
| Employees |
19 |
|
|
| www.hemispherx.net
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Treatment of viral and immune-based disorders |
|
| Management |
| William A. Carter, M.D., Chairman of the Board, Chief Executive Officer; Charles T. Bernhardt, Chief Financial Officer; David R. Strayer, M.D. Medical Director - Regulatory Affairs; Carol A. Smith, Ph.D., Vice President, Manufacturing Quality Assurance and Process Development; William A. Carter, M.D., Chairman of the Board, President, Chief Executive Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| immunotherapeutics, ampligen, oragens, glycosylated, alpha interferon |
|
|
|
| Description |
|
Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx’s flagship products include Alferon N Injection and the experimental immunotherapeutics/antivirals Ampligen and Oragens. Hemispherx’s platform technology includes large and small agent components for potential treatment of various viral infections. Hemispherx has in excess of 100 patents comprising its core intellectual property estate covering various forms of double stranded (ds) RNA and their fields of therapeutic application, a fully commercialized product (Alferon N) and a GMP certified manufacturing facilities for its novel pharma products in New Brunswick, New Jersey. |
|
| Products / Services |
ALFERON N Injection [Interferon alfa-n3 (human leukocyte derived)] is the Company's registered trademark for its injectable formulation of Natural Alpha Interferon, approved by the U.S. Food and Drug Administration (FDA) for the intralesional treatment of refractory or recurring external condylomata acuminata in patients 18 years of age or older.
|
|
| Technology / Differentiation |
| IFN antiviral actions inhibit viral messenger RNA (mRNA) synthesis, viral assembly, viral packaging, and release of virions. |
|
| Market / Customers |
Ampligen, is a new class of specifically-configured ribonucleic acid (RNA) compounds targeted at such important diseases as Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME), HIV, Hepatitis B, Hepatitis C, and cancers including kidney cancer and metastatic malignant melanoma. Alferon N is targeted at genital HPV (refractory condylomata acuminata), Hepatitis C, HIV, West Nile Virus, and SARS.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
